Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1

Min.Order: 10 Gram
Payment Terms: T/T,Other

Product Details

Keywords

Montelukast sodium
mk-476
151767-02-1

Quick Details

ProName: Montelukast sodium CAS No. 151767-02-1
CasNo: 151767-02-1
Molecular Formula: C35H35ClNNaO3S
Appearance: White crystallized powder
Application: medical intermediate
DeliveryTime: Wihtin 5-7 Days
PackAge: A variety of packing ways for your cho...
Port: Wuhan / Shanghai / Guangzhou ...
ProductionCapacity: 5 Kilogram/Month
Purity: 99%
Storage: Kept in a well-closed, light-resistant...
Transportation: EMS, HKEMS, DHL, TNT, UPS, Fedex....
LimitNum: 10 Gram

Superiority

1. Best prices with satisfied quality;

2. It's clients' right to choose the package's Courier (EMS, DHL, FedEx, UPS);

3. It's clients' right to choose the packing way for his produccts from many recent effective packing ways;

4. Specials are possible when client's order is big enough, including the discount policy;

5. Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;

Details

Montelukast sodium Basic information

Pharmacological effect Application

Product Name:	Montelukast sodium
Synonyms:	singulair;MONTELUKAST NA;MONTELUKAST SODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476, Singulair;Montelukast, Sodium Salt
CAS:	151767-02-1
MF:	C35H35ClNNaO3S
MW:	608.17
EINECS:
Product Categories:	Active Pharmaceutical Ingredients;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Isotope Labeled Compounds;Pharmaceutical intermediates;DIOXYLINE;Other APIs;Inhibitors

Montelukast sodium Chemical Properties,Usage,Production

Pharmacological effect
Cysteinyl leukotrienes (LTC4, LTD4, LTE4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. These important asthma pre-inflammatory mediators can bind to the Cysteinyl leukotriene receptors (CysLT) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation.
Montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. It was successfully developed by the Merck Company (German) and had entered into market in Canada, Finland, and Mexican in 1997. It is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment.
Montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. It is also a potent oral preparation that can significantly improve the inflammatory indicators. Biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the CysLT1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β- adrenergic receptors). Montelukast can effectively suppress the physiological effects caused by the binding between LTC4, LTD4 and LTE4 receptor and CysLT1 receptor without any receptor agonistic activity. There is the secondary type of cysteinyl leukotriene receptor (CysLT2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. So far, researchers haven’t cloned two receptors so the situation of CysLT receptor is illustrated through binding assay and pharmacological analysis. It has been now thought that montelukast does not antagonize CysLT2 receptors.
The above information is edited by the chemicalbook of Dai Xiongfeng.

Application
It can be applied to alleviate the symptoms caused by allergic rhinitis.

Usage
A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic

Usage
antiinfective

Usage
A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity